Valsartan Amlodipine Randomized Trial (VART): Design, Methods, and Preliminary Results View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2008-01

AUTHORS

Keiko Nakayama, Yoichi Kuwabara, Masao Daimon, Satoshi Shindo, Miwa Fujita, Hiroya Narumi, Hiroshi Mizuma, Issei Komuro

ABSTRACT

Antihypertensive therapy has been well established to reduce hypertension-related morbidity and mortality, but the optimal therapy for Japanese patients remains unknown. The Valsartan Amlodipine Randomized Trial (VART), a prospective randomized open-label trial, was designed to determine whether treatment with an angiotensin II type 1 receptor blocker (valsartan) or a calcium channel blocker (amlodipine) lowers cardiovascular disease events in essential hypertensives in Japan. Registration, randomization and data entry were performed over the Internet. The minimization method (to control for age, gender, blood pressure level and history) was used at random assignment to ensure that the background factors were equivalent between the groups at baseline. After the registration, patients were followed-up for cardiovascular events (primary endpoints), echocardiography, 123I-metaiodobenzylguanidine (MIBG) imaging, laboratory tests and blood pressure for 3 years. Currently, 797 patients have been enrolled and assigned to two groups: a valsartan (n=399) and an amlodipine (n=398) group. At baseline, controlled factors (age, gender, blood pressure level, and left ventricular hypertrophy) and the proportions of patients with diabetes and hyperlipidemia were equally allocated. At 12 months, both drugs evenly and significantly lowered blood pressure to the target level (valsartan: 133/79 mmHg; amlodipine: 132/79 mmHg). In conclusion, by combining the data on cardiovascular events with the results of echocardiographic, radionuclide imaging, and blood/urine studies, the VART study will provide mechanistic insights into the clinical outcomes and treatment effects of the trial. (Hypertens Res 2008; 31: 21−28) More... »

PAGES

21-28

References to SciGraph publications

Identifiers

URI

http://scigraph.springernature.com/pub.10.1291/hypres.31.21

DOI

http://dx.doi.org/10.1291/hypres.31.21

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1010763509

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/18360014


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "3-Iodobenzylguanidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Amlodipine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Angiotensin II Type 1 Receptor Blockers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antihypertensive Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Calcium Channel Blockers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Data Interpretation, Statistical", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Endpoint Determination", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Follow-Up Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Hypertension", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Informed Consent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Middle Aged", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Patient Selection", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Prospective Studies", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radionuclide Imaging", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Radiopharmaceuticals", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Research Design", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Risk Factors", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sample Size", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Tetrazoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Ultrasonography", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Valine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Valsartan", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Nakayama", 
        "givenName": "Keiko", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kuwabara", 
        "givenName": "Yoichi", 
        "id": "sg:person.0752532133.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752532133.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Daimon", 
        "givenName": "Masao", 
        "id": "sg:person.01312065070.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312065070.00"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shindo", 
        "givenName": "Satoshi", 
        "id": "sg:person.01066760533.40", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066760533.40"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Fujita", 
        "givenName": "Miwa", 
        "id": "sg:person.01135073733.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135073733.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Narumi", 
        "givenName": "Hiroya", 
        "id": "sg:person.01203207133.99", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203207133.99"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Mizuma", 
        "givenName": "Hiroshi", 
        "id": "sg:person.01251322333.16", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251322333.16"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan", 
          "id": "http://www.grid.ac/institutes/grid.136304.3", 
          "name": [
            "Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Komuro", 
        "givenName": "Issei", 
        "id": "sg:person.01012024207.33", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012024207.33"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.2165/00003495-199447060-00005", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034980850", 
          "https://doi.org/10.2165/00003495-199447060-00005"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1291/hypres.28.865", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050983237", 
          "https://doi.org/10.1291/hypres.28.865"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2008-01", 
    "datePublishedReg": "2008-01-01", 
    "description": "Antihypertensive therapy has been well established to reduce hypertension-related morbidity and mortality, but the optimal therapy for Japanese patients remains unknown. The Valsartan Amlodipine Randomized Trial (VART), a prospective randomized open-label trial, was designed to determine whether treatment with an angiotensin II type 1 receptor blocker (valsartan) or a calcium channel blocker (amlodipine) lowers cardiovascular disease events in essential hypertensives in Japan. Registration, randomization and data entry were performed over the Internet. The minimization method (to control for age, gender, blood pressure level and history) was used at random assignment to ensure that the background factors were equivalent between the groups at baseline. After the registration, patients were followed-up for cardiovascular events (primary endpoints), echocardiography, 123I-metaiodobenzylguanidine (MIBG) imaging, laboratory tests and blood pressure for 3 years. Currently, 797 patients have been enrolled and assigned to two groups: a valsartan (n=399) and an amlodipine (n=398) group. At baseline, controlled factors (age, gender, blood pressure level, and left ventricular hypertrophy) and the proportions of patients with diabetes and hyperlipidemia were equally allocated. At 12 months, both drugs evenly and significantly lowered blood pressure to the target level (valsartan: 133/79 mmHg; amlodipine: 132/79 mmHg). In conclusion, by combining the data on cardiovascular events with the results of echocardiographic, radionuclide imaging, and blood/urine studies, the VART study will provide mechanistic insights into the clinical outcomes and treatment effects of the trial. (Hypertens Res 2008; 31: 21\u221228)", 
    "genre": "article", 
    "id": "sg:pub.10.1291/hypres.31.21", 
    "inLanguage": "en", 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1313717", 
        "issn": [
          "0916-9636", 
          "1348-4214"
        ], 
        "name": "Hypertension Research", 
        "publisher": "Japanese Society of Hypertension", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "31"
      }
    ], 
    "keywords": [
      "cardiovascular events", 
      "blood pressure", 
      "randomized trials", 
      "angiotensin II type 1 receptor blocker", 
      "open-label trial", 
      "type 1 receptor blocker", 
      "hypertension-related morbidity", 
      "cardiovascular disease events", 
      "proportion of patients", 
      "calcium channel blockers", 
      "amlodipine group", 
      "antihypertensive therapy", 
      "receptor blockers", 
      "optimal therapy", 
      "essential hypertensives", 
      "clinical outcomes", 
      "disease events", 
      "Japanese patients", 
      "urine studies", 
      "channel blockers", 
      "patients", 
      "trials", 
      "treatment effects", 
      "therapy", 
      "blockers", 
      "background factors", 
      "baseline", 
      "random assignment", 
      "laboratory tests", 
      "target level", 
      "group", 
      "hypertensives", 
      "morbidity", 
      "echocardiography", 
      "hyperlipidemia", 
      "diabetes", 
      "valsartan", 
      "mortality", 
      "months", 
      "data entry", 
      "drugs", 
      "outcomes", 
      "factors", 
      "treatment", 
      "events", 
      "mechanistic insights", 
      "randomization", 
      "study", 
      "imaging", 
      "conclusion", 
      "pressure", 
      "preliminary results", 
      "years", 
      "proportion", 
      "levels", 
      "registration", 
      "test", 
      "entry", 
      "effect", 
      "results", 
      "data", 
      "method", 
      "Japan", 
      "radionuclides", 
      "insights", 
      "design", 
      "assignment", 
      "Internet", 
      "minimization method", 
      "Valsartan Amlodipine Randomized Trial", 
      "Amlodipine Randomized Trial", 
      "II type 1 receptor blocker", 
      "blood/urine studies", 
      "VART study"
    ], 
    "name": "Valsartan Amlodipine Randomized Trial (VART): Design, Methods, and Preliminary Results", 
    "pagination": "21-28", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1010763509"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1291/hypres.31.21"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "18360014"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1291/hypres.31.21", 
      "https://app.dimensions.ai/details/publication/pub.1010763509"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2022-01-01T18:18", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20220101/entities/gbq_results/article/article_456.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1291/hypres.31.21"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1291/hypres.31.21'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1291/hypres.31.21'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1291/hypres.31.21'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1291/hypres.31.21'


 

This table displays all metadata directly associated to this object as RDF triples.

296 TRIPLES      22 PREDICATES      129 URIs      119 LITERALS      33 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1291/hypres.31.21 schema:about N0508f99925bd44e5b1ac5c965e419c8a
2 N12b7a77d48b44f9f94cbac7f2f746f27
3 N1c82a4957d684b4e89b483f334940355
4 N20f8cc8b8cc644afb8dce598f514cb6d
5 N2632fb8dd696427e8ddf230c53648fc0
6 N34fff5c4c3f748adbe02ad667879a016
7 N4c526dcd74d94d089fe718c690aa953f
8 N5161679564664477a8fa3de842d2c03d
9 N680db264a5cb4296884f489febf6ddfe
10 N8303fc01dca74b29a3d4ad86bc8ddc31
11 N94a3b539b6de459390a85690a6fa18fb
12 N967c28f000bf4430859ff4b5c730ba2e
13 Na6a11eb71fa94d07966fbacd568fcef1
14 Na9d38d1fe9db4d4395c40d45c792ce1c
15 Nad997fa923c1464e88afa83f09b532ba
16 Nbebf88f6b87f42c7bdeaa501f636fda2
17 Nc0d67aab85e64511a87eb5a28aa5c403
18 Ncf28d37bbd3f41a3bfa259f1b15d0a71
19 Nd5c46f5fb3bf4e8cb13bde4bb44c511e
20 Nda03aa0912b64d35aaa8922f1847bc24
21 Ne514c773ed23490e9bb4905ad9f710c4
22 Ne7048beac5c6466d9f26b120957976f3
23 Ne8a6322ca32140f8b8d42ab088bade7c
24 Nea779b8c3e6f487fb0047fc975005687
25 Nebb751dc9a7a4e1c94d82c9a494bb2fb
26 Nfde20f5125a04820932027a8d6390065
27 anzsrc-for:11
28 anzsrc-for:1102
29 schema:author Nb975fa0734d146dda9bc01489368b653
30 schema:citation sg:pub.10.1291/hypres.28.865
31 sg:pub.10.2165/00003495-199447060-00005
32 schema:datePublished 2008-01
33 schema:datePublishedReg 2008-01-01
34 schema:description Antihypertensive therapy has been well established to reduce hypertension-related morbidity and mortality, but the optimal therapy for Japanese patients remains unknown. The Valsartan Amlodipine Randomized Trial (VART), a prospective randomized open-label trial, was designed to determine whether treatment with an angiotensin II type 1 receptor blocker (valsartan) or a calcium channel blocker (amlodipine) lowers cardiovascular disease events in essential hypertensives in Japan. Registration, randomization and data entry were performed over the Internet. The minimization method (to control for age, gender, blood pressure level and history) was used at random assignment to ensure that the background factors were equivalent between the groups at baseline. After the registration, patients were followed-up for cardiovascular events (primary endpoints), echocardiography, 123I-metaiodobenzylguanidine (MIBG) imaging, laboratory tests and blood pressure for 3 years. Currently, 797 patients have been enrolled and assigned to two groups: a valsartan (n=399) and an amlodipine (n=398) group. At baseline, controlled factors (age, gender, blood pressure level, and left ventricular hypertrophy) and the proportions of patients with diabetes and hyperlipidemia were equally allocated. At 12 months, both drugs evenly and significantly lowered blood pressure to the target level (valsartan: 133/79 mmHg; amlodipine: 132/79 mmHg). In conclusion, by combining the data on cardiovascular events with the results of echocardiographic, radionuclide imaging, and blood/urine studies, the VART study will provide mechanistic insights into the clinical outcomes and treatment effects of the trial. (Hypertens Res 2008; 31: 21−28)
35 schema:genre article
36 schema:inLanguage en
37 schema:isAccessibleForFree true
38 schema:isPartOf N7488f3eb54664e3d9feaa139b96fe1c2
39 Nf2b62d20f6ff4f77b6c3af6d45ea7be6
40 sg:journal.1313717
41 schema:keywords Amlodipine Randomized Trial
42 II type 1 receptor blocker
43 Internet
44 Japan
45 Japanese patients
46 VART study
47 Valsartan Amlodipine Randomized Trial
48 amlodipine group
49 angiotensin II type 1 receptor blocker
50 antihypertensive therapy
51 assignment
52 background factors
53 baseline
54 blockers
55 blood pressure
56 blood/urine studies
57 calcium channel blockers
58 cardiovascular disease events
59 cardiovascular events
60 channel blockers
61 clinical outcomes
62 conclusion
63 data
64 data entry
65 design
66 diabetes
67 disease events
68 drugs
69 echocardiography
70 effect
71 entry
72 essential hypertensives
73 events
74 factors
75 group
76 hyperlipidemia
77 hypertension-related morbidity
78 hypertensives
79 imaging
80 insights
81 laboratory tests
82 levels
83 mechanistic insights
84 method
85 minimization method
86 months
87 morbidity
88 mortality
89 open-label trial
90 optimal therapy
91 outcomes
92 patients
93 preliminary results
94 pressure
95 proportion
96 proportion of patients
97 radionuclides
98 random assignment
99 randomization
100 randomized trials
101 receptor blockers
102 registration
103 results
104 study
105 target level
106 test
107 therapy
108 treatment
109 treatment effects
110 trials
111 type 1 receptor blocker
112 urine studies
113 valsartan
114 years
115 schema:name Valsartan Amlodipine Randomized Trial (VART): Design, Methods, and Preliminary Results
116 schema:pagination 21-28
117 schema:productId N33839807800d4d1591a7b5b2d8c34010
118 N5344d0be414d41839f25ad55fa819a51
119 Ncf650edc34a04ac8ae22ae37a20994e0
120 schema:sameAs https://app.dimensions.ai/details/publication/pub.1010763509
121 https://doi.org/10.1291/hypres.31.21
122 schema:sdDatePublished 2022-01-01T18:18
123 schema:sdLicense https://scigraph.springernature.com/explorer/license/
124 schema:sdPublisher Nfaf9368d5c734638a44844e26b25ea81
125 schema:url https://doi.org/10.1291/hypres.31.21
126 sgo:license sg:explorer/license/
127 sgo:sdDataset articles
128 rdf:type schema:ScholarlyArticle
129 N0508f99925bd44e5b1ac5c965e419c8a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
130 schema:name Female
131 rdf:type schema:DefinedTerm
132 N12b7a77d48b44f9f94cbac7f2f746f27 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
133 schema:name Humans
134 rdf:type schema:DefinedTerm
135 N1c82a4957d684b4e89b483f334940355 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
136 schema:name Radiopharmaceuticals
137 rdf:type schema:DefinedTerm
138 N20f8cc8b8cc644afb8dce598f514cb6d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Radionuclide Imaging
140 rdf:type schema:DefinedTerm
141 N2632fb8dd696427e8ddf230c53648fc0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
142 schema:name Hypertension
143 rdf:type schema:DefinedTerm
144 N2ad6bccde7e14b95a4b3ae879837212b rdf:first sg:person.0752532133.65
145 rdf:rest N4d5a696db79e4f4a80674e706693e4c0
146 N33839807800d4d1591a7b5b2d8c34010 schema:name dimensions_id
147 schema:value pub.1010763509
148 rdf:type schema:PropertyValue
149 N34fff5c4c3f748adbe02ad667879a016 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
150 schema:name Aged
151 rdf:type schema:DefinedTerm
152 N41a8419ab1d74ec58d1f76127f37ff1e rdf:first sg:person.01012024207.33
153 rdf:rest rdf:nil
154 N4c526dcd74d94d089fe718c690aa953f schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
155 schema:name Ultrasonography
156 rdf:type schema:DefinedTerm
157 N4d5a696db79e4f4a80674e706693e4c0 rdf:first sg:person.01312065070.00
158 rdf:rest Nfb0889c769e14e33bbffcf10e839d035
159 N5161679564664477a8fa3de842d2c03d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
160 schema:name Prospective Studies
161 rdf:type schema:DefinedTerm
162 N5344d0be414d41839f25ad55fa819a51 schema:name doi
163 schema:value 10.1291/hypres.31.21
164 rdf:type schema:PropertyValue
165 N680db264a5cb4296884f489febf6ddfe schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Risk Factors
167 rdf:type schema:DefinedTerm
168 N7488f3eb54664e3d9feaa139b96fe1c2 schema:volumeNumber 31
169 rdf:type schema:PublicationVolume
170 N8115f8d9811f4db9b347144055cda5a3 rdf:first sg:person.01135073733.57
171 rdf:rest Nb72ffecd92d246099f91b9b9eec39f4e
172 N8303fc01dca74b29a3d4ad86bc8ddc31 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
173 schema:name Patient Selection
174 rdf:type schema:DefinedTerm
175 N94a3b539b6de459390a85690a6fa18fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
176 schema:name Middle Aged
177 rdf:type schema:DefinedTerm
178 N967c28f000bf4430859ff4b5c730ba2e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
179 schema:name Amlodipine
180 rdf:type schema:DefinedTerm
181 N9e07a9e12e6b4ff59bf3d024b5d7d185 schema:affiliation grid-institutes:grid.136304.3
182 schema:familyName Nakayama
183 schema:givenName Keiko
184 rdf:type schema:Person
185 Na6a11eb71fa94d07966fbacd568fcef1 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
186 schema:name Valine
187 rdf:type schema:DefinedTerm
188 Na9d38d1fe9db4d4395c40d45c792ce1c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
189 schema:name Data Interpretation, Statistical
190 rdf:type schema:DefinedTerm
191 Nad997fa923c1464e88afa83f09b532ba schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
192 schema:name Valsartan
193 rdf:type schema:DefinedTerm
194 Nb72ffecd92d246099f91b9b9eec39f4e rdf:first sg:person.01203207133.99
195 rdf:rest Ncc74c99d61a34b5ca8f0137b6366bc5a
196 Nb975fa0734d146dda9bc01489368b653 rdf:first N9e07a9e12e6b4ff59bf3d024b5d7d185
197 rdf:rest N2ad6bccde7e14b95a4b3ae879837212b
198 Nbebf88f6b87f42c7bdeaa501f636fda2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
199 schema:name Male
200 rdf:type schema:DefinedTerm
201 Nc0d67aab85e64511a87eb5a28aa5c403 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
202 schema:name Research Design
203 rdf:type schema:DefinedTerm
204 Ncc74c99d61a34b5ca8f0137b6366bc5a rdf:first sg:person.01251322333.16
205 rdf:rest N41a8419ab1d74ec58d1f76127f37ff1e
206 Ncf28d37bbd3f41a3bfa259f1b15d0a71 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
207 schema:name Endpoint Determination
208 rdf:type schema:DefinedTerm
209 Ncf650edc34a04ac8ae22ae37a20994e0 schema:name pubmed_id
210 schema:value 18360014
211 rdf:type schema:PropertyValue
212 Nd5c46f5fb3bf4e8cb13bde4bb44c511e schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
213 schema:name Follow-Up Studies
214 rdf:type schema:DefinedTerm
215 Nda03aa0912b64d35aaa8922f1847bc24 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
216 schema:name 3-Iodobenzylguanidine
217 rdf:type schema:DefinedTerm
218 Ne514c773ed23490e9bb4905ad9f710c4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
219 schema:name Angiotensin II Type 1 Receptor Blockers
220 rdf:type schema:DefinedTerm
221 Ne7048beac5c6466d9f26b120957976f3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
222 schema:name Antihypertensive Agents
223 rdf:type schema:DefinedTerm
224 Ne8a6322ca32140f8b8d42ab088bade7c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
225 schema:name Tetrazoles
226 rdf:type schema:DefinedTerm
227 Nea779b8c3e6f487fb0047fc975005687 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
228 schema:name Sample Size
229 rdf:type schema:DefinedTerm
230 Nebb751dc9a7a4e1c94d82c9a494bb2fb schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
231 schema:name Informed Consent
232 rdf:type schema:DefinedTerm
233 Nf2b62d20f6ff4f77b6c3af6d45ea7be6 schema:issueNumber 1
234 rdf:type schema:PublicationIssue
235 Nfaf9368d5c734638a44844e26b25ea81 schema:name Springer Nature - SN SciGraph project
236 rdf:type schema:Organization
237 Nfb0889c769e14e33bbffcf10e839d035 rdf:first sg:person.01066760533.40
238 rdf:rest N8115f8d9811f4db9b347144055cda5a3
239 Nfde20f5125a04820932027a8d6390065 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
240 schema:name Calcium Channel Blockers
241 rdf:type schema:DefinedTerm
242 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
243 schema:name Medical and Health Sciences
244 rdf:type schema:DefinedTerm
245 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
246 schema:name Cardiorespiratory Medicine and Haematology
247 rdf:type schema:DefinedTerm
248 sg:journal.1313717 schema:issn 0916-9636
249 1348-4214
250 schema:name Hypertension Research
251 schema:publisher Japanese Society of Hypertension
252 rdf:type schema:Periodical
253 sg:person.01012024207.33 schema:affiliation grid-institutes:grid.136304.3
254 schema:familyName Komuro
255 schema:givenName Issei
256 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01012024207.33
257 rdf:type schema:Person
258 sg:person.01066760533.40 schema:affiliation grid-institutes:grid.136304.3
259 schema:familyName Shindo
260 schema:givenName Satoshi
261 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01066760533.40
262 rdf:type schema:Person
263 sg:person.01135073733.57 schema:affiliation grid-institutes:grid.136304.3
264 schema:familyName Fujita
265 schema:givenName Miwa
266 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01135073733.57
267 rdf:type schema:Person
268 sg:person.01203207133.99 schema:affiliation grid-institutes:grid.136304.3
269 schema:familyName Narumi
270 schema:givenName Hiroya
271 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203207133.99
272 rdf:type schema:Person
273 sg:person.01251322333.16 schema:affiliation grid-institutes:grid.136304.3
274 schema:familyName Mizuma
275 schema:givenName Hiroshi
276 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01251322333.16
277 rdf:type schema:Person
278 sg:person.01312065070.00 schema:affiliation grid-institutes:grid.136304.3
279 schema:familyName Daimon
280 schema:givenName Masao
281 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01312065070.00
282 rdf:type schema:Person
283 sg:person.0752532133.65 schema:affiliation grid-institutes:grid.136304.3
284 schema:familyName Kuwabara
285 schema:givenName Yoichi
286 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0752532133.65
287 rdf:type schema:Person
288 sg:pub.10.1291/hypres.28.865 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050983237
289 https://doi.org/10.1291/hypres.28.865
290 rdf:type schema:CreativeWork
291 sg:pub.10.2165/00003495-199447060-00005 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034980850
292 https://doi.org/10.2165/00003495-199447060-00005
293 rdf:type schema:CreativeWork
294 grid-institutes:grid.136304.3 schema:alternateName Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
295 schema:name Department of Cardiovascular Science and Medicine, Chiba University Graduate School of Medicine, Chiba, Japan
296 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...